about
Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data.Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital dataBeyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia.Investigating adverse events following immunisation with pneumococcal polysaccharide vaccine using electronic General Practice data.Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses.Evaluating the implementation of the 13-valent pneumococcal vaccine supplementary dose program in Australian primary health care settings.Estimating vaccine coverage from serial trivariate serologic data in the presence of waning immunity.No evidence of increasing Haemophilus influenzae non-b infection in Australian Aboriginal children.Influenza and pneumococcal vaccination in Australian adults: a systematic review of coverage and factors associated with uptakeModern trends in mortality from meningococcal disease in Australia.Immunisation issues for Indigenous Australian children.Intussusception after monovalent human rotavirus vaccine in Australia: severity and comparison of using healthcare database records versus case confirmation to assess risk.Predicting localised measles outbreak potential in Australia.Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.Control of varicella in the post-vaccination era in Australia: a model-based assessment of catch-up and infant vaccination strategies for the future.Equity in disease prevention: Vaccines for the older adults - a national workshop, Australia 2014.Models of strategies for control of rubella and congenital rubella syndrome-a 40 year experience from Australia.Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical.Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.Pneumonia in Elderly Australians: Reduction in Presumptive Pneumococcal Hospitalizations but No Change in All-Cause Pneumonia Hospitalizations Following 7-Valent Pneumococcal Conjugate Vaccination.Long-term trends in invasive Haemophilus influenzae type B disease among indigenous Australian children following use of PRP-OMP and PRP-T vaccines.Cytomegalovirus-related childhood mortality in Australia 1999-2011.Mortality from Herpes Simplex Virus (HSV) Infection in Australian Children, 1999-2011 Using National Datasets.The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia.Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program.The association of respiratory viruses, temperature, and other climatic parameters with the incidence of invasive pneumococcal disease in Sydney, Australia.Determining the contribution of <em>Streptococcus pneumoniae</em> to community-acquired pneumonia in Australia.Current epidemiology of rubella and congenital rubella syndrome in Australia: progress towards elimination.Control of varicella in the post-vaccination era in Australia: a model-based assessment of catch-up and infant vaccination strategies for the future - CORRIGENDUM.Vaccine preventable diseases and vaccination policy for indigenous populations.The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia.Vaccine preventable diseases in indigenous populations - International perspectives. Satellite Symposium of the 5th International Symposium on Pneumococci and Pneumococcal Diseases, April 2006, Alice Springs, Australia.Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older.Higher pertussis hospitalization rates in indigenous Australian infants, and delayed vaccination.Effectiveness of Seven and Thirteen Valent Pneumococcal Conjugate Vaccines in a Schedule without a Booster dose: a Ten Year Observational Study.Vaccine myopia: adult vaccination also needs attention.Vaccine myopia: adult vaccination also needs attention.Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in AustraliaGeneral practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events
P50
Q30842343-91CC2FF7-3924-4DD5-9FF2-14F81512DB4BQ31041736-8EE48A2F-4CE1-4E73-824A-A392A7D5C0EDQ31146806-659DABAA-7494-4892-AFA4-C06BBD946EBCQ31162238-FBBB34C5-88F2-455E-A3D0-853BF96E6EB1Q34389227-EC2C7D91-A1D0-49F8-8F58-22108879BE48Q35497140-E0C96275-983C-4FBA-866D-B6BE2BEF8712Q35575813-537ED631-C618-4979-ABFE-D4F5901F12EDQ37120547-972FF844-B4E1-4C55-BF6C-7113D03F6331Q37286084-400975E8-80FC-45CC-8A83-B6B5F1191531Q37621933-E32C4119-419C-4AC8-82CB-9B93197145EEQ37874686-0C57308F-8AEC-4FF3-91D5-12C9E6430E60Q38206065-A2E0B997-49D2-4231-A8F9-A3AB3E5161F1Q39050021-CB4A4723-215E-441E-8AF4-9F3CB50A3582Q39093634-B380DCF5-023C-471D-BA10-8513CE3B3FBDQ39128973-5FDBCAC8-7959-4BD7-8220-32943B6DE541Q39337544-30275557-ED73-4ADD-B96E-D43F076557A9Q39511242-A981473E-A5BA-4739-BC4F-DCF6479C6D65Q40141107-421EF8A6-4521-40A9-AE44-A8B70CE166A2Q40221821-DB825571-FA30-43C7-B291-7D6A0553DF03Q40372606-9B0FA372-0C53-4D54-B6CC-63C44C319A80Q40844795-15BB2DD2-4EBA-428F-8088-59939EFEB525Q40940306-BEBE3ED4-B525-4395-8430-76745CD033F1Q41075344-1B95D7E1-EDC1-402E-8268-21151212E3C3Q42206333-61ED18C1-B296-4599-89FD-D540F3A651FDQ43705213-C3AD90C9-5C77-4D4A-AD68-CC3797622B88Q46798238-145C77AD-1211-4ECE-96BC-7A3DA93B44F9Q47674299-019CAB24-6F7B-4CBE-A26F-59EF8B328928Q47675094-00BD11C5-55EA-4203-BF32-9F10CCCED5DFQ47814545-FC3CEF0D-EF58-4F6E-9D50-2B27E4906495Q48579634-48049C8D-27C7-4E4F-9919-411E98D6AF34Q50158522-43C5688B-DF50-4FAE-B302-F8F4387D7FE7Q50208558-3E48E8CF-DBE1-4067-A903-6DD61A066CB0Q50665571-00F6919D-2EA9-4FC9-9290-3CCF7E422FFBQ51472665-1A85B822-EC47-42E1-B8E7-53A935719C93Q51721197-7AA8B8FD-03D0-4FD9-BF3C-F117E25AE099Q52689646-35D4E235-C167-4CE2-88A4-5C6A02E34151Q52839094-8BD8507C-EF48-45CB-91FA-EC80588BCF23Q53766362-DC23AF24-2D15-4E08-8F82-B842A1D289C1Q57132233-BE36062A-BCC4-417D-84B7-57B93DA915BFQ59602368-9E351B81-1AEB-498B-949E-98B2970BB187
P50
description
investigador
@es
researcher
@en
name
Robert Menzies
@en
Robert Menzies
@nl
type
label
Robert Menzies
@en
Robert Menzies
@nl
prefLabel
Robert Menzies
@en
Robert Menzies
@nl
P31
P496
0000-0003-3833-5765